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Abstract Sialic acids comprise a family of terminal sugars
essential for a variety of biological recognition systems.
N-Propanoylmannosamine, an unphysiological sialic acid pre-
cursor, is taken up and metabolized by mammalian cells resulting
in oligosaccharide-bound N-propanoylneuraminic acid. N-Pro-
panoylmannosamine, applied to endogenously hyposialylated
subclones of the myeloid leukemia HL60 and of the B-cell
lymphoma BJA-B, both deficient in UDP-N-acetylglucosamine
2-epimerase, is efficiently metabolized to CMP-N-propanoyl-
neuraminic acid resulting in up to 85% of glycoconjugate-
associated sialic acids being unphysiological N-propanoylneur-
aminic acid. Thus, UDP-N-acetylglucosamine 2-epimerase-
deficient cell lines provide an important experimental progress
in engineering cells to display an almost homogeneous population
of defined, structurally altered sialic acids. ß 2001 Published
by Elsevier Science B.V. on behalf of the Federation of Euro-
pean Biochemical Societies.
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1. Introduction
Sialic acids are the most abundant terminal sugar moieties
on the surface of eukaryotic cells. As a component of oligo-
saccharides on glycoconjugates, sialic acids are crucial for
many biological processes, such as cellular adhesion [1], for-
mation or masking of recognition determinants [2,3], and sta-
bilization of the structure of glycoproteins [4]. Also, cell sur-
face sialylation has been implicated in the tumorigenicity and
metastatic behavior of malignant cells [5,6].
Sialic acid analogues have frequently been employed in in
vitro systems to shed light on the role of sialic acids and
speci¢c side groups of these 9-carbon aminosugars for sialic
acid-dependent cell^cell or pathogen^cell interactions [7,8].
More recently, through the development of unphysiological
N-substituted D-mannosamine derivatives N-acyl side chain
modi¢cations of sialic acids could also be introduced into
living cells (for review see Keppler et al. [9]). These synthetic
D-mannosamines were shown to be taken up by cells, metab-
olized by the promiscuous sialic acid biosynthetic pathway,
and expressed as N-acyl-modi¢ed sialic acids on the cell sur-
face. A number of subsequent studies have demonstrated a
crucial role of the N-acyl side chain in various biological pro-
cesses, including the binding of several viruses to their cellular
sialoglycoconjugate receptors [10,11], the proliferation of neu-
ronal cells [12], the density-dependent inhibition of prolifera-
tion in human ¢broblasts [13] and the binding of myelin-as-
sociated glycoprotein to neuronal cells [14].
Synthetic D-mannosamine derivatives likely compete with
the physiological precursor N-acetylmannosamine (ManNAc)
and its metabolic products for the sialic acid biosynthetic
machinery, resulting in low to moderate rates of the expres-
sion of modi¢ed sialic acids on the cell surface. We therefore
hypothesized that in the absence of this physiological compe-
tition the incorporation e⁄ciency of structurally altered,
N-acyl-modi¢ed sialic acids could be further increased. To test
this we exposed two recently identi¢ed, endogenously hypo-
sialylated hematopoietic cell lines to N-propanoylmannos-
amine (ManNProp). Due to a lack of UDP-N-acetylglucos-
amine 2-epimerase (UDP-GlcNAc 2-epimerase), the key
enzyme of sialic acid biosynthesis, subclones of the myeloid
leukemia HL60 (HL60-I) and the B-cell lymphoma BJA-B
(BJA-B K20) cannot synthesize ManNAc and sialic acid de
novo. These endogenously hyposialylated cells are only able
to recruit a small amount of sialic acids from serum sialogly-
coconjugates, probably through a salvage pathway [15]. Here
we demonstrate that up to 85% of the total cellular sialic acids
can be engineered to carry unphysiological N-propanoyl res-
idues in these cell lines.
2. Materials and methods
2.1. Materials
ManNProp was chemically synthesized as previously described [16].
Fluorescein isothiocyanate (FITC)-conjugated Limax £avus agglutinin
(LFA) was from EY Laboratories (San Mateo, CA, USA). All other
chemicals were from Sigma (Deisenhofen, Germany).
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2.2. Cell culture and sugar treatment
The hyposialylated subclones HL60-I, spontaneously derived from
wild-type HL60 cells [15], BJA-B K20, produced by limited dilution of
BJA-B cells [17], and two normally sialylated reference cell lines,
HL60-II and BJA-B K88 were propagated as suspension cultures in
RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum,
2 mM glutamine, 100 U of penicillin per ml, and 100 Wg of strepto-
mycin per ml in a humidi¢ed 5% CO2, 37‡C atmosphere. Stock solu-
tions of ManNAc or ManNProp were prepared by dissolving the
sugars in medium and subsequent ¢lter sterilization. Cells were seeded
at 3U105/ml, sugars were added to concentrations of 10 mM, if not
indicated otherwise, and cells were cultured in the presence or absence
of the sugars for the indicated time periods.
2.3. Quanti¢cation of cellular CMP-sialic acids
CMP-sialic acids were prepared and determined by the method of
Fritsch et al. [18]. In brief, cells (1^2U107) were sonicated in 2 ml of
50 mM ammonium hydrogencarbonate, pH 8.0, and the lysate was
centrifuged at 100 000Ug for 30 min. Protein was precipitated by
adjusting the supernatant to 70% ethanol. The soluble fraction was
applied to a DEAE-Sephacel column. The column was washed with
water, sialic acids were quantitatively washed out with 20 mM am-
monium acetate, CMP-sialic acids were eluted with 70 mM ammo-
nium acetate. CMP-sialic acids were analyzed by Dionex high per-
formance anion exchange chromatography (HPAEC) using a
CarboPac PA-100 column. CMP-sialic acid content was given as
nmol/mg of protein. For determination of relative amounts of
CMP-N-acetylneuraminic acid (CMP-NeuAc) and CMP-N-propa-
noylneuraminic acid (CMP-NeuProp) in cellular CMP-sialic acid frac-
tions, sialic acids were released for 1 h with 2 M acetic acid at 80‡C
[19] and N-acylneuraminic acids were analyzed by HPLC as described
below.
2.4. Quanti¢cation of membrane-bound sialic acids and
N-acylneuraminic acids
PBS-washed cells (1U107) were lysed by hypotonic shock in 1 ml
water (15 min, 4‡C). The crude membrane fraction was pelleted by
centrifugation at 10 000Ug for 15 min. The pellet was washed twice
with water and lyophilized. Content of membrane glycoconjugate-
bound sialic acid was determined by hydrolyzing the pellet for 1 h
with 2 M acetic acid at 80‡C [19]. Sialic acids were quanti¢ed by the
thiobarbituric acid method [20] and HPLC analysis, as described be-
low. Similar results were obtained by both methods.
NeuAc and NeuProp were quanti¢ed by HPLC analysis. pH values
of the acetic acid hydrolysates were adjusted to 4 and further puri¢-
cation was carried out on a cation exchanger (AG-50W-X12, H
form; Bio-Rad, Mu«nchen, Germany). N-acetylneuraminic acids were
£uorescence-labeled according to a method of Hara et al. [21] and
analyzed on a reversed-phase C18 column as described [10].
2.5. Flow cytometry analysis
Cells (2U106) were washed twice in cold PBS and subsequently
incubated in 100 Wl PBS containing FITC-labeled lectins, either 20
Wg/ml LFA or 50 Wg/ml Vicia villosa agglutinin (VVA), for 45 min
on ice in the dark. After washing with PBS cells were resuspended in
500 Wl PBS and analyzed by £ow cytometry on a Beckton Dickinson
FACScan using Cellquest II software.
3. Results and discussion
3.1. Quanti¢cation of membrane-bound sialic acids
To test whether hyposialylated cells can metabolize and
incorporate unphysiological, N-acyl-modi¢ed mannosamines
more e⁄ciently, we cultivated HL60-I and BJA-B K20, and
two normally sialylated reference cell lines, HL60-II and BJA-
B K88 [15,17], in the presence of ManNProp. In a ¢rst experi-
ment hyposialylated HL60-I and BJA-B K20 cells were culti-
vated in the presence of 10 mM ManNAc or ManNProp for
3 days and subsequently, the membrane-bound sialic acid
content was quanti¢ed by the thiobarbituric acid method
(Table 1). This assay detects both N-acetyl- and N-propanoyl-
neuraminic acids [20].
In HL60-I and BJA-B K20 cells ManNAc and ManNProp
treatment increased sialylation, approximately 5- and 3-fold,
respectively (Table 1). N-Acylmannosamine-treated K20 cells
even reached the sialylation status of normally sialylated K88
cells. This suggests that the physiological and unphysiological
sialic acid precursor had been metabolized to the respective
N-acylneuraminic acids at a similar rate and these had then
been incorporated into cell surface glycoconjugates. The over-
all sialic acid content of UDP-GlcNAc 2-epimerase-competent
HL60-II and BJA-B K88 cells was una¡ected by either
D-mannosamine derivative probably re£ecting a preexisting
saturation of all acceptor sites for sialic acid in these cells.
Next, we analyzed cell surface sialylation in ManNAc- and
ManNProp-treated cells by £ow cytometry using two £uoro-
chrome-labeled sialic acid-sensitive lectins. In agreement with
the results described above, both ManNAc- and ManNProp-
treated HL60-I cells showed a drastically increased binding of
the sialic acid-speci¢c lectin LFA (Fig. 1), indicative of an
increased cell surface sialylation. Interestingly, the increase
in LFA binding in ManNProp-treated cells was about 2-fold
less than that of ManNAc-treated cells. As shown in Table 1
this is not due to a lower cell surface sialylation in Man-
NProp-treated cells. Most likely it re£ects a reduced binding
a⁄nity of LFA to N-propanoyl-modi¢ed sialic acids. This is
supported by data obtained for the second lectin, VVA, which
recognizes penultimate carbohydrate structures that can be
masked by sialic acids [17]. VVA showed an equivalent or
even slightly higher reduction in ManNProp-treated com-
Table 1
CMP-sialic acids and membrane-bound sialic acids in HL60 and BJA-B subclones with or without sugar treatment
Cells Sialic acid content (nmol/107 cells) CMP-sialic acid content (nmol/107 cells)
HL60-I 0.2 þ 0.1 6 0.02
HL60-I+ManNAc 1.2 þ 0.4 0.24 þ 0.04
HL60-I+ManNProp 1.0 þ 0.4 0.26 þ 0.06
HL60-II 2.5 þ 0.4 0.28 þ 0.06
HL60-II+ManNAc 2.8 þ 0.8 1.04 þ 0.12
HL60-II+ManNProp 2.8 þ 0.7 0.26 þ 0.08
BJA-B K20 1.0 þ 0.3 6 0.02
BJA-B K20+ManNAc 2.9 þ 0.4 1.06 þ 0.14
BJA-B K20+ManNProp 3.1 þ 0.4 0.78 þ 0.16
BJA-B K88 3.1 þ 0.5 0.34 þ 0.08
BJA-B K88+ManNAc 3.3 þ 0.6 2.50 þ 0.04
BJA-B K88+ManNProp 3.0 þ 0.4 1.12 þ 0.06
Cells were incubated with 10 mM ManNAc or ManNProp for 3 days. CMP-sialic acid content was determined by HPAEC analysis, sialic acid
content was determined by the thiobarbituric acid method. Values are means þ S.D. of four (sialic acid content) and three (CMP-sialic acid con-
tent) values, respectively.
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pared to ManNAc-treated HL60-I cells (Fig. 1). Furthermore,
a model of the sialic acid binding site of LFA has been pre-
viously proposed, in which an important role of the N-acetyl
group for the interaction with this lectin was put forward [22],
suggesting that an aliphatic elongation of N-acyl side chain
could interfere with lectin binding. In HL60-II cells no signi¢-
cant changes in LFA or VVA binding were observed (Fig. 2).
This is consistent with the unchanged total sialic acid content
of these cells after sugar treatment and with the low percent-
age of structurally altered sialic acids following ManNProp
treatment (Fig. 3).
3.2. Determination of CMP-sialic acids
In order to gain further insight into the metabolism of ex-
ternally applied N-acylmannosamines in both UDP-GlcNAc
2-epimerase-de¢cient and -competent cells, we investigated the
intracellular CMP-sialic acid pool. In human cells CMP-acti-
vated sialic acids are normally found as CMP-NeuAc, since
no formation of CMP-N-glycolylneuraminic acid takes place
due to a defect in the respective hydroxylase [23,24]. Other
sialic acid modi¢cations, including O-acetylation and O-meth-
ylation, occur after transfer of NeuAc to oligosaccharide
chains on glycoconjugates [3]. In untreated BJA-B K20 cells
a CMP-NeuAc peak could not be unambiguously de¢ned
(Fig. 2A) and their CMP-NeuAc concentration was accord-
ingly set to be lower than 0.02 nmol/107 cells, which is the
limit of detection of this assay [18]. After treatment of BJA-B
K20 cells with ManNAc the chromatogram displayed a peak
(Fig. 2B) with an identical elution time and elution pro¢le as
commercially available CMP-NeuAc and as CMP-NeuAc de-
tected in BJA-B K88 cells (data not shown).
Treatment of BJA-B K20 cells with ManNProp resulted in
a distinct elution peak with a slightly shorter elution time (0.4
min) compared to CMP-NeuAc (Fig. 2C). This is consistent
with the small structural di¡erence between CMP-NeuAc and
CMP-NeuProp, the latter representing the dominant species
of CMP-sialic acid expected to be synthesized in ManNProp-
treated K20 cells. However, the only minor di¡erence in elu-
Fig. 1. Detection of cell surface sialic acids by £ow cytometry in HL60 subclones with or without sugar treatment. Histograms illustrate the ex-
pression of sialic acids (LFA) or unmasked penultimate N-acetylgalactosamine residues (VVA) on the cell surface of hyposialylated HL60-I and
normally sialylated HL60-II cells as determined by £ow cytometry. Cells were treated with ManNAc or ManNProp for 3 days. The histograms
for untreated cells (light gray) and cells without lectin staining (dark gray) are shown as references.
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tion times between the CMP-activated N-acetyl and N-prop-
anoylneuraminic acids prevented a clear di¡erentiation of the
two compounds in mixed populations, in particular in cell
lines with an intact de novo sialic acid biosynthesis. Conse-
quently, the HPAEC analysis was only used for quanti¢cation
of the total CMP-sialic acid pool.
In both hyposialylated cell lines CMP-sialic acid pools be-
came detectable only after treatment with N-acylmannos-
amines (Table 1). Interestingly, also the CMP-sialic acid
pool of ManNAc-treated HL60-II and BJA-B K88 cells,
and of ManNProp-treated K88 cells, increased signi¢cantly.
This is in agreement with results of Fritsch et al. [18] and
indicates a bypass of the tightly regulated feedback function
of UDP-GlcNAc 2-epimerase [25] by supplying the sialic acid
biosynthetic pathway with the epimerase reaction product
ManNAc, or its unphysiological N-propanoyl analogue. No-
tably, both HL60-II and BJA-B K88 cells showed a preference
for the physiological ManNAc, as indicated by a higher CMP-
sialic acid concentration in cells treated with ManNAc or
ManNProp at equimolar concentrations. Despite the well
documented general promiscuity of the sialic acid biosynthetic
machinery towards N-acyl modi¢cations [9], these results im-
ply either a reduced uptake or a less e⁄cient metabolism of
the N-propanoyl analogue to the respective CMP-sialic acid in
these cells.
3.3. Relative amounts of N-propanoyl-modi¢ed membrane-
bound sialic acids and CMP-sialic acids
For an unambiguous discrimination of NeuAc and Neu-
Prop we used HPLC analysis on a reversed-phase column
[10]. In a ¢rst experiment the relative amount of glycosidi-
cally-linked NeuProp on the cell surface of ManNProp-
treated cells was investigated over the course of 4 days (Fig.
3). ManNProp treatment at 10 mM for only one day resulted
in the expression of signi¢cant levels of NeuProp on the cell
surface of HL60 and BJA-B cells. Maximal incorporation of
the unphysiological precursor was reached after about 3 days.
Treatment of cells at 5 mM resulted in a very similar kinetic,
but the overall incorporation levels were between 12% (HL60-
I) and 40% (HL60-II) lower than those at 10 mM (data not
shown).
The kinetics are consistent with data from Ferwerda et al.
[26], which showed a maximal incorporation of [3H]ManNAc
into sialic acids of rat brain glycoconjugates after about
2 days. Since £ux of these compounds through the sialic
acid biosynthetic pathway is thought only to take a few hours
[26], these much longer intervals for cells to reach maximal
incorporation most likely re£ect the relatively slow turnover
of sialic acids on preexisting cellular glycoconjugates. The
average half-life of sialic acid on liver cell surface glycopro-
teins is in the range of 25^30 h [27]. Consequently, up to
3 days are required to reach maximal replacement of NeuAc
by NeuProp in normally sialylated cells.
The ratios of relative concentrations of physiological and
unphysiological CMP-sialic acids and membrane-bound sialic
acids in HL60-I and HL60-II cells were almost identical (Fig.
4). In contrast, both BJA-B subclones showed a lower relative
percentage of N-propanoyl-modi¢ed compounds in the sialic
acid fraction as compared to the CMP-sialic acid fraction.
These ¢ndings suggest that in HL60 cells the Golgi CMP-
sialic acid transporter as well as the most active sialyltransfer-
Fig. 2. Detection of cellular CMP-sialic acids after treatment with
N-acylmannosamines. The CMP-sialic acid fraction was isolated
from (A) untreated, (B) ManNAc-treated, or (C) ManNProp-treated
BJA-B K20 cells (10 mM, 3 days) and analyzed by HPAEC as de-
scribed in Section 2. At about 31 min a constant, sample-derived
but unidenti¢ed peak appeared, which served as internal standard.
Fig. 3. Kinetic of ManNProp incorporation into membrane-bound
sialic acids. Cells were treated with ManNProp (10 mM) and, at the
indicated time points, the relative concentration of NeuProp in
membrane-bound sialic acids was determined by HPLC analysis.
Values are means of two independent experiments.
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ases utilize CMP-NeuProp and CMP-NeuAc with comparable
e⁄ciency. The drop in the relative representation of the
N-propanoyl metabolite in the sialic acid fraction in BJA-B
cells could, for example, be explained by a lower a⁄nity of
one or several of the most prominent sialyltransferases in
these B-cells.
The most e⁄cient NeuProp incorporation was found in
HL60-I and BJA-B K20 cells, both of which are UDP-
GlcNAc 2-epimerase-de¢cient (Fig. 3). In contrast, HL60-II
cells, which display a high UDP-GlcNAc 2-epimerase activity
(50 þ 11 WU/mg of protein [15]), showed a relative NeuProp
incorporation of only 15% after 3 days of ManNProp treat-
ment. In BJA-B K88 cells with a moderate 2-epimerase activ-
ity (18 þ 2 WU/mg of protein [15]) 56% of total sialic acids
were structurally modi¢ed. These results show an inverse cor-
relation between the incorporation of unphysiological N-acyl-
mannosamines into sialic acids and the activity of UDP-
GlcNAc 2-epimerase. Di¡erent levels of UDP-GlcNAc 2-epi-
merase activity probably translate into di¡erent amounts of
intracellular ManNAc being synthesized, which compete di-
rectly with ManNProp for advancing in the biosynthetic path-
way. This is underlined by results from Yarema et al. [28],
showing that in Jurkat cells with a hyperactive UDP-GlcNAc
2-epimerase of the sialuria type almost no modi¢ed sialic acids
were incorporated after treatment with modi¢ed mannos-
amine precursors due to an extremely high production level
of competing ManNAc.
The very e¡ective incorporation of NeuProp in the hypo-
sialylated subclones resulted in up to 85% modi¢ed sialic acids
in cell surface sialoglycoconjugates. A similar e⁄ciency has
only been described for peracetylated mannosamine precur-
sors (up to 80% [14]). Therefore, the combination of synthetic
N-acylmannosamine treatment with UDP-GlcNAc 2-epimer-
ase-de¢cient cells can be used for the engineering of cells with
almost homogeneous populations of modi¢ed sialic acids,
which should further improve the studies of sialic acid-depen-
dent ligand^receptor interactions.
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Fig. 4. Relative amounts of N-propanoyl-modi¢ed membrane-bound
sialic acids and CMP-sialic acids in HL60 and BJA-B subclones
after treatment with ManNProp. Cells were treated with ManNProp
(10 mM) for 3 days. CMP-sialic acids and membrane-bound sialic
acids were puri¢ed, sialic acids were released by acetic acid hydroly-
sis, and the percentage of NeuProp in total sialic acids was deter-
mined by reversed-phase HPLC analysis. Values for membrane-
bound sialic acids represent the arithmetic means þ S.D. of four in-
dependent determinations. Values for CMP-sialic acids are arith-
metic means of two independent determinations where relative dif-
ferences between determinations were less than 5%.
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